ADVERTISEMENT
LIVE DESK·Global markets desk·Last updated 14s ago
ADVERTISEMENT
Markets/EquitiesArticle

Denmark’s OMX Copenhagen 20 slips 0.22% as Maersk drags

The OMX Copenhagen 20 fell 0.22% Tuesday, led by a 3.7% drop in A.P. Moller-Maersk shares. Coloplast and Novo Nordisk advanced, while gold and oil futures moved higher.

PA
Priya Anand · Equities & Earnings Desk · 19 Aug 2026 · 16:41 · 1 min read
Share
Denmark’s OMX Copenhagen 20 slips 0.22% as Maersk drags

Denmark’s benchmark equity gauge, the OMX Copenhagen 20, closed 0.22% lower on Tuesday as losses in shipping and industrial stocks offset gains in healthcare and technology shares.

Declining issues slightly outnumbered advancers by 61 to 60, with 17 stocks unchanged on the Copenhagen exchange. The index slipped 0.22% to end the session following broad weakness in the personal and household goods, software, and technology sectors.

Top performers included Coloplast, which rose 3.0% to 435.60 Danish kroner, and Novo Nordisk Class B shares, which added 1.35% to 296.40. Demant also edged higher by 0.27% to 295.20.

Heavyweight A.P. Moller-Maersk led the declines, with both its A and B shares falling more than 3%. The B-share class dropped 3.7% to 20,830.00, while the A-share class fell 3.37% to 20,100.00. Rockwool also retreated 3.12% to 224.00.

Commodities showed mixed performance, with October crude oil rising 1.33% to $84.85 per barrel and Brent crude up 1.07% to $91.84. December gold futures, however, fell 1.42% to $4,410.07 per troy ounce.

The Danish krone held steady against major peers, with the USD/DKK exchange rate virtually unchanged at 6.46 and EUR/DKK at 7.48. The U.S. Dollar Index futures were flat at 99.54.

This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
Novara — A Smarter Way to Access Global Markets
Share this story
PA
Written by
Priya Anand
Equities & Earnings Desk

Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.

More from Priya Anand →
ADVERTISEMENT
ADVERTISEMENT